How to use my portfolios

How to use my portfolios

We’ve had a big influx of new readers here at JubakAM.com thanks to the magic of groundhogs and our Groundhog Day 20% off deal. And I’ve received a number of questions that boil down to How do I get started using the five portfolios on the site? Here’s my advice.

To rebalance my Volatility Portfolio I’m selling my Nektar May 18 call options

Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug

In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo

Volatility Portfolio up 53% in 2017

Volatility Portfolio up 53% in 2017

When I started my Volatility Portfolio back in January 2017, I really didn’t have much more in mind than a conviction that in this market traders and investors and traders could score market beating returns from taking advantage of market and economic volatility. I didn’t narrow my approach to volatility to one or two aspects or markets, but instead followed a wide menu approach to volatility as a characteristic stretching across markets from real estate to bonds to education to stocks. That menu as based on the research I’d done for my February 2016 book Juggling with Knives: Smart Investing in the Coming Age of Volatility. Certainly the return on this portfolio for its first year of operation confirm this wide-menu approach. The portfolio showed a total return of 53.06%–assuming equal initial weightings in each position–as of December 31, 2017. That qualifies, I’d say, as beating the market in 2017. The total return on the Standard & Poor’s 500 stock index was 21.64% in 2017. But in that first year of operation I found a more focused goal for the Volatility Portfolio too.

To rebalance my Volatility Portfolio I’m selling my Nektar May 18 call options

Nektar soars today on J.P. Morgan healthcare conference

Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech conference. The slides from the company’s presentation today are in circulation but CEO Howard Robin doesn’t actually present until 2 p.m. New York time today.

Argentina gets credit rating boost from Moody’s–good news for my Volatility Portfolio picks GGAL and ARGT

Argentina gets credit rating boost from Moody’s–good news for my Volatility Portfolio picks GGAL and ARGT

Yesterday Moody’s Investors Service raised Argentina’s credit rating one level to B2 from B3. I added Grupo Financiero Galicia (GGAL) and Global X MSCI Argentina ETF (ARGT) to my Volatility Portfolio on my expectation that President Mauricio Macri’s macroeconomic reforms would gradually revive the economy and lead to upgrades in the country’s credit rating (and a drop in runaway inflation.)  The two picks are up 69.12% and 7.29%, respectively, since I added them to this portfolio. Argentina is on track, Moody’s said in its upgrade, to turn in two years of economic growth in a row in 2017 and 2108, which would be the first time that’s happened since 2011. Moody’s projects that the Argentine economy will grow by 3% this year and 3.5% in 2018.